Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
262 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00656136 | BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) | completed | Phase 3 | 585 | Boehringer IngelheimINDUSTRY | 15 | Jul 26, 2016 | clinicaltrials |
| NCT01325428 | Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer | completed | Phase 2 | 26 | Boehringer IngelheimINDUSTRY | 7 | Jul 19, 2016 | clinicaltrials |
| NCT01251653 | A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel | completed | — | 94 | Boehringer IngelheimINDUSTRY | 1 | May 30, 2016 | clinicaltrials |
| NCT00987935 | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | completed | Phase 2 | 134 | Boehringer IngelheimINDUSTRY | 2 | Mar 10, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01335269 | A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer | completed | Phase 1 | 96 | Boehringer IngelheimINDUSTRY | 2 | Dec 9, 2015 | clinicaltrials |
| NCT01090011 | Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer | completed | Phase 1 | 171 | Boehringer IngelheimINDUSTRY | 2 | Oct 2, 2015 | clinicaltrials |
| NCT00632749 | BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | completed | Phase 2 | 68 | Boehringer IngelheimINDUSTRY | 1 | Sep 14, 2015 | clinicaltrials |
| NCT01441596 | Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases | completed | Phase 2 | 121 | Boehringer IngelheimINDUSTRY | 8 | Sep 7, 2015 | clinicaltrials |
| NCT00998296 | Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. | completed | Phase 1 | 70 | Boehringer IngelheimINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01121406 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | completed | Phase 2 | 110 | Boehringer IngelheimINDUSTRY | 5 | Aug 13, 2015 | clinicaltrials |
| NCT00904839 | BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer | completed | Phase 2 | 128 | Boehringer IngelheimINDUSTRY | 5 | Feb 4, 2015 | clinicaltrials |
| NCT02171663 | Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 0 | Jan 28, 2015 | clinicaltrials |
| NCT00706628 | A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer | completed | Phase 2 | 87 | Boehringer IngelheimINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00711594 | LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | completed | Phase 2 | 74 | Boehringer IngelheimINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT01329549 | Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Nov 27, 2014 | clinicaltrials |
| NCT02254044 | Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus | terminated | Phase 1 | 7 | Boehringer IngelheimINDUSTRY | 0 | Oct 1, 2014 | clinicaltrials |
| NCT01905111 | A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer | completed | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 2 | Sep 4, 2014 | clinicaltrials |
| NCT02215044 | Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer | terminated | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 0 | Aug 13, 2014 | clinicaltrials |
| NCT02215733 | The Use of Angiotensin Receptor Blockers and the Risk of Cancer | completed | — | 1,165,781 | Boehringer IngelheimINDUSTRY | 0 | Aug 13, 2014 | clinicaltrials |
| NCT02211833 | Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer | completed | Phase 1 | 41 | Boehringer IngelheimINDUSTRY | 0 | Aug 8, 2014 | clinicaltrials |
| NCT02211872 | BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit | completed | Phase 1 | 63 | Boehringer IngelheimINDUSTRY | 0 | Aug 8, 2014 | clinicaltrials |
| NCT02209701 | Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors | terminated | Phase 1 | 3 | Boehringer IngelheimINDUSTRY | 0 | Aug 6, 2014 | clinicaltrials |
| NCT02209727 | Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 9 | Boehringer IngelheimINDUSTRY | 0 | Aug 6, 2014 | clinicaltrials |
| NCT02203864 | Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma | completed | Phase 1 | 49 | Boehringer IngelheimINDUSTRY | 0 | Jul 31, 2014 | clinicaltrials |
| NCT02204033 | Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer | completed | Phase 1 | 33 | Boehringer IngelheimINDUSTRY | 0 | Jul 30, 2014 | clinicaltrials |
| NCT02204046 | Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast | completed | Phase 1 | 9 | Boehringer IngelheimINDUSTRY | 0 | Jul 30, 2014 | clinicaltrials |
| NCT02204059 | Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Boehringer IngelheimINDUSTRY | 0 | Jul 30, 2014 | clinicaltrials |
| NCT02199886 | Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection | terminated | Phase 1 | 6 | Boehringer IngelheimINDUSTRY | 0 | Jul 25, 2014 | clinicaltrials |
| NCT02198274 | Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 25 | Boehringer IngelheimINDUSTRY | 0 | Jul 23, 2014 | clinicaltrials |
| NCT00701324 | BI 811283 in Various Solid Tumours | completed | Phase 1 | 124 | Boehringer IngelheimINDUSTRY | 1 | Jul 22, 2014 | clinicaltrials |
| NCT00796549 | BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients | completed | Phase 2 | 70 | Boehringer IngelheimINDUSTRY | 1 | Jul 22, 2014 | clinicaltrials |
| NCT02182102 | Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer | completed | Phase 1 | 26 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT02182128 | A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 24 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT02182141 | An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 17 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT02182206 | An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours | completed | Phase 1 | 50 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT02182232 | A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | completed | Phase 1 | 33 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT02183246 | Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients | terminated | Phase 3 | 3 | Boehringer IngelheimINDUSTRY | 0 | Jul 8, 2014 | clinicaltrials |
| NCT01152437 | A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 94 | Boehringer IngelheimINDUSTRY | 1 | Jun 26, 2014 | clinicaltrials |
| NCT02171637 | Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | Boehringer IngelheimINDUSTRY | 0 | Jun 24, 2014 | clinicaltrials |
| NCT02171676 | BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Boehringer IngelheimINDUSTRY | 0 | Jun 24, 2014 | clinicaltrials |
| NCT02171702 | Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours | completed | Phase 1 | 53 | Boehringer IngelheimINDUSTRY | 0 | Jun 24, 2014 | clinicaltrials |
| NCT02171728 | Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 0 | Jun 24, 2014 | clinicaltrials |
| NCT02171741 | Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors | completed | Phase 1 | 31 | Boehringer IngelheimINDUSTRY | 0 | Jun 24, 2014 | clinicaltrials |
| NCT00431067 | Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy | completed | Phase 2 | 41 | Boehringer IngelheimINDUSTRY | 2 | Jun 9, 2014 | clinicaltrials |
| NCT00906698 | Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2 | completed | Phase 1 | 55 | Boehringer IngelheimINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT01169675 | BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours | completed | Phase 1 | 53 | Boehringer IngelheimINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials